.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Teva
Baxter
McKinsey
Mallinckrodt
Cipla
Merck
Covington
Johnson and Johnson
Fuji

Generated: September 21, 2017

DrugPatentWatch Database Preview

NIASPAN Drug Profile

« Back to Dashboard

Which patents cover Niaspan, and when can generic versions of Niaspan launch?

Niaspan is a drug marketed by Abbvie and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-nine patent family members in ten countries.

The generic ingredient in NIASPAN is niacin. There are fourteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the niacin profile page.

Summary for Tradename: NIASPAN

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list9
Bulk Api Vendors: see list107
Clinical Trials: see list39
Patent Applications: see list9,507
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NIASPAN at DailyMed

Pharmacology for Tradename: NIASPAN

Ingredient-typeNicotinic Acids
Drug ClassNicotinic Acid
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
NIASPAN TITRATION STARTER PACK
niacin
TABLET, EXTENDED RELEASE;ORAL020381-005Jul 28, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-004Jul 28, 1997ABRXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-002Jul 28, 1997ABRXYesNo► Subscribe► Subscribe ► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-003Jul 28, 1997ABRXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-004Jul 28, 1997ABRXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-003Jul 28, 1997ABRXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-002Jul 28, 1997ABRXYesNo► Subscribe► Subscribe ► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-001Jul 28, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NIASPAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-003Jul 28, 1997► Subscribe► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-001Jul 28, 1997► Subscribe► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-003Jul 28, 1997► Subscribe► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-002Jul 28, 1997► Subscribe► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-003Jul 28, 1997► Subscribe► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-001Jul 28, 1997► Subscribe► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-004Jul 28, 1997► Subscribe► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-004Jul 28, 1997► Subscribe► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-003Jul 28, 1997► Subscribe► Subscribe
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381-002Jul 28, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: NIASPAN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,129,930 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night► Subscribe
6,818,229 Intermediate release nicotinic acid compositions for treating hyperlipidemia► Subscribe
6,746,691 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics► Subscribe
6,676,967 Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia► Subscribe
6,406,715 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles► Subscribe
7,998,506Nicotinic acid compositions for treating hyperlipidemia and related methods therefor► Subscribe
7,011,848Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NIASPAN

Country Document Number Estimated Expiration
European Patent Office0643965► Subscribe
Australia6454598► Subscribe
Finland991896► Subscribe
Germany69829042► Subscribe
World Intellectual Property Organization (WIPO)9839002► Subscribe
European Patent Office0999844► Subscribe
Norway994248► Subscribe
Australia8605298► Subscribe
Canada2283322► Subscribe
Norway20000406► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
McKesson
Fish and Richardson
Medtronic
Argus Health
US Department of Justice
Julphar
Boehringer Ingelheim
Federal Trade Commission
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot